ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 637 • 2017 ACR/ARHP Annual Meeting

    The Effect of Biologic Therapies on the Gut Microbial Composition in Psoriatic Arthritis

    Julia Manasson1, Carles Ubeda2, Lu Yang3, Melania Fanok4, Gary E. Solomon1, Soumya M. Reddy5, Sergei Koralov6, Jose C. Clemente7 and Jose U. Scher1,4, 1Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Institute for Research in Public Health, Valencia, Spain, 3New York University School of Medicine, New York, NY, 4New York University School of Medicine, New York, NY, 5Department of Medicine, Division of Rheumatology *contributed equally, New York University School of Medicine, New York, NY, 6Pathology, New York University School of Medicine, New York, NY, 7Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis affecting multiple clinical domains. If left untreated, it has the potential for significant morbidity and disability.…
  • Abstract Number: 638 • 2017 ACR/ARHP Annual Meeting

    Are There Clinical Demographic or Subclinical Ultrasonographic Data That Can Predict Flare in Psoriatic Arthritis Patients during a Phase of Minimal Disease Activity after Spacing of Anti-TNF Blockers Injections?

    Pierluigi Macchioni1, Giovanni Ciancio2, Gilda Sandri3, Alen Zabotti4, Luca Montaguti5, Gentiana Vukatana6, Fabio Mascella7, Donatella Chessa8, Elisa Verduci9, Marcello Govoni10, Amelia Spinella3, Francesca Zuliani11, Marco Bruschi5, Nazzarena Malavolta12 and Mariacristina Focherini7, 1Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 2Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-Universitaria Sant’Anna - Ferrara (Italy), ferrara, Italy, 3Rheumatology Unit, University fo Modena & Reggio, Modena, Italy, 4Rheumatology Clinic, Department of Medical and Biological Sciences, Santa Maria della Misericordia" University Hospital, Udine, Italy, 5Dipartimento Internistico SS di Reumatologia, AUSL Romagna Ospedale Bufalini, Cesena, Italy, 6Rheumatology Unit, Department CardioThoracic Vascular, S.Orsola- Malpighi Hospital, Alma Mater Studiorum, Bologna, Bologna, Italy, 7Internal Medicine and Rheumatology, Ospedale Infermi Rimini, Rimini, Italy, 8Internal Medicine, Ospedale Paolo Dettori, Tempio Pausania, Italy, 9Rheumatology Unit, Arcispedale S. Maria Nuova, Reggio Emilia, Italy, 10Rheumatology Clinic, Department of Medical and Biological Sciences, University of Ferrara and Azienda Ospedaliera-Universitaria Sant’Anna - Ferrara (Italy), ferrara, Italy, 11Rheumatology Unit, Department of Medical Sciences, Santa Maria della Misericordia" University Hospital, Udine, Italy, 12Policlinico S.Orsola-Malpighi, Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy

    Background/Purpose: Tumour necrosis factor (TNF)-blocker tapering has been proposed for patients with psoriatic arthritis (PA) in clinical remission. To evaluate if there are clinical, demographic…
  • Abstract Number: 639 • 2017 ACR/ARHP Annual Meeting

    Clinical and Sonographic Analysis of Patients with Psoriasis without Musculoskeletal Complaints. Preeliminary Results of a Prospective Study: The PRE-Psa Cohort

    Andrea Cuervo1, Julio Ramírez2, Merce Alsina3, Raimon Sanmarti4 and Juan D. Cañete5, 1Arthritis Unit. Rheumatology Dpt, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, 2Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 3Dermatology Dpt, Hospital Clinic de Barcelona, Barcelona, Spain, 4Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, 5Arthritis Unit. Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain

    Background/Purpose: Early diagnosis in psoriatic arthritis (PsA) is mandatory in order to initiate early therapy and prevent disability. Around 20% of patients with Psoriasis (PsO)…
  • Abstract Number: 640 • 2017 ACR/ARHP Annual Meeting

    Is There a Relationship between Spondyloarthritis and Periodontitis? a Case-Control Study

    Wilson Bautista-Molano1, Désirée van der Heijde2, Robert B.M. Landewé3, Gloria Lafaurie4, Julieth De Avila4, Rafael Valle-Oñate5 and Consuelo Romero-Sanchez6, 1School of Medicine, Universidad Militar Nueva Granada and Rheumatology Department Hospital Militar, Colombia, Bogotá, Colombia, 2Leiden University Medical Center, Leiden, Netherlands, 3University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, 4Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, Colombia, Bogotá, Colombia, 5School of Medicine, Universidad Militar Nueva Granada and Rheumatology Department Hospital Militar, Colombia, Bogota, Colombia, 6Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, Colombia, BOGOTA, Colombia

    Background/Purpose: Knowledge of the existence of an epidemiological association between SpA and periodontitis may fuel pathophysiological thinking about SpA and if established, have clinical implications.…
  • Abstract Number: 641 • 2017 ACR/ARHP Annual Meeting

    Children with Treatment-Naive Enthesitis-Related Arthritis Have Decreased Fecal Abundance of Faecalibacterium Prausnitzii A2-165 and Bacteroides Fragilis: A Multi-Center Collaborative Study

    Matthew L. Stoll1, Pamela F. Weiss2, Jennifer E. Weiss3, Peter Nigrovic4, Barbara Edelheit5, S. Louis Bridges Jr.6, Maria I. Danila7, Charles Spencer8, Marilynn Punaro9, Kenneth Schikler10, Andreas Reiff11, Ranjit Kumar12, Randy Q. Cron1, Casey D Morrow13 and Elliot J. Lefkowitz14, 1Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, 3Hackensack University Medical Center, Hackensack, NJ, 4Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Pediatric Rheumatology, Connecticut Childrens Medical Center, Hartford, CT, 6Clinical Immunology & Rheum, Univ of Alabama, Birmingham, AL, 7University of Alabama at Birmingham, Birmingham, AL, 8Rheumatology, Nationwide Childrens Hospital/OSU, Columbus, OH, 9Children's Health, Dallas, TX, 10University of Louisville Medical School, Louisville, KY, 11Children’s Hospital of Los Angeles, Los Angeles, CA, 12Center for Clinical and Translational Sciences, University of Alabama at Birmingham, Birmingham, AL, 13Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, 14Microbiology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Prior studies have demonstrated abnormalities in the composition of the gastrointestinal microbiota in pediatric and adult patients with spondyloarthritis (SpA.) In particular, diminished fecal…
  • Abstract Number: 642 • 2017 ACR/ARHP Annual Meeting

    Downstream Effects of Apremilast in Human Arthritic Ex Vivo Models

    Tue Wenzel Kragstrup1,2, Søren Lomholt2, Morten Aagaard Nielsen2, Line Dam Heftdal2, Peter H. Schafer3 and Bent Deleuran2,4, 1Randers Regional Hospital, Randers, Denmark, 2Department of Biomedicine, Aarhus University, Aarhus, Denmark, 3Department of Translational Development, Celgene Corporation, Summit, NJ, 4Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: Apremilast (Otezla) is a PDE4 inhibitor approved for the treatment of psoriasis and psoriatic arthritis, but the mechanisms of action of apremilast are not…
  • Abstract Number: 643 • 2017 ACR/ARHP Annual Meeting

    Mir-10b-5p Is a IL-22 Regulator in CD4+T Cells from Ankylosing Spondylitis

    Tae-Jong Kim1, So-Hee Jin2, Liye Chen3, Mohammad Hussein Al-Mossawi3, Anna Ridley3, Takuya Sekine3, Davide Simone3, Hui Shi3, Frank Penkava3 and Paul Bowness3, 1Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South), 2Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South), 3Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

    Background/Purpose: Emerging data suggest that a single microRNA (miR) can profoundly alter the phenotype and outcome of immune responses, offering the prospect of therapeutic use.…
  • Abstract Number: 644 • 2017 ACR/ARHP Annual Meeting

    Association of Osteonectin, Osteopontin and Osteocalcin with Inflammation and Cardiovascular Risk in Patients with Axial Spondyloarthritis

    Fernanda Genre1, Javier Rueda-Gotor2, Juan Irure-Ventura3, Sara Remuzgo-Martínez1, Alfonso Corrales1, Begoña Ubilla1, Veronica Mijares1, Carlos Fernández-Díaz1, Virginia Portilla1, Ricardo Blanco1, Javier Llorca4, J. Gonzalo Ocejo-Vinyals3, Raquel López-Mejías1 and Miguel Angel González-Gay5, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Immunology Division, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, 5Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL and School of Medicine, University of Cantabria, Santander, Spain

    Background/Purpose: A higher incidence of cardiovascular (CV) risk factors and atherosclerosis has been reported in axial spondyloarthritis (axSpA) patients1. Since axSpA (particularly AS) is an…
  • Abstract Number: 645 • 2017 ACR/ARHP Annual Meeting

    An Oral Tyk2 Inhibitor Effectively Suppresses the Development of Murine Th17 Cells In Vivo and Prevents Joint Damage in Experimental Ankylosing Spondylitis

    Eric Gracey1,2, Melissa Lim2, Zoya Qaiyum1, Yuriy Baglaenko1,2, Wenyan Miao3, Craig Masse3, William Westlin3 and Robert D Inman1,4, 1Department of Immunology, University of Toronto, Toronto, ON, Canada, 2Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 3Nimbus Therapeutics, Cambridge, MA, 4Toronto Western Hospital, University Health Network, toronto, ON, Canada

    Background/Purpose: Th17 cells play an important role in the pathogenesis of ankylosing spondylitis (AS). Tyk2, a member of the Janus Kinase (JAK) family of signaling…
  • Abstract Number: 646 • 2017 ACR/ARHP Annual Meeting

    Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Is a Susceptibility Factor for Early Axial Spa Meeting the ASAS Classification Criteria: Results from the Spondyloarthritis Caught Early and DEvenir des Spondyloarthrites Indifférenciées Récentes Cohorts

    Anoek de Koning1, Marjolijn Hameetman2, Corinne Miceli-Richard3, Maxime Dougados4, Désirée van der Heijde5, Fina Kurreeman6 and Floris van Gaalen7, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Department of Rheumatology, Hôpital Bicêtre, Paris, France, 4Department of Rheumatology, Rene Descartes University, Hôpital Cochin, Paris, France, 5Leiden University Medical Center, Leiden, Netherlands, 6Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Leiden, Netherlands, 7Rheumatology, LUMC, Leiden, Netherlands

    Background/Purpose: Genetic research in axSpA is performed in patients with longstanding ankylosing spondylitis (AS). Early axial spondyloarthritis (axSpA) is a diverse patient group in which…
  • Abstract Number: 647 • 2017 ACR/ARHP Annual Meeting

    Gene Expression in Cellular Subsets in Psoriatic Disease

    Anastasiya Muntyanu1, Fatima Abji2, Remy Pollock1, Vinod Chandran2 and Dafna D Gladman2, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis is an inflammatory musculoskeletal disease which develops in 30% of patients with psoriasis. Our previous peripheral blood microarray study identified CXCL10, NOTCH2NL,…
  • Abstract Number: 648 • 2017 ACR/ARHP Annual Meeting

    Are Choline Metabolites Associated with Inflammation in Psoriatic Arthritis?

    Roxana Coras1,2, Arthur Kavanaugh2, Doquyen Huynh3, Mohit Jain2 and Monica Guma2, 1Medicine, Autonomous University of Barcelona, Barcelona, Spain, 2Medicine, University of California, San Diego, La Jolla, CA, 3Medicine, University of California, San Diego, San Diego, CA

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease affecting the joints and connective tissue and is associated with psoriasis of the skin and nails. In…
  • Abstract Number: 649 • 2017 ACR/ARHP Annual Meeting

    Role of Eicosanoids As Biomarkers in Psoriatic Arthritis

    Roxana Coras1,2, Arthur Kavanaugh1, Doquyen H. Huynh1, Aladdin Shadyab3, Sara Marsal4, Oswald Quehenberger5 and Monica Guma1, 1Medicine, University of California, San Diego, La Jolla, CA, 2Medicine, Autonomous University of Barcelona, Barcelona, Spain, 3Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, 4Rheumatology Research Unit, Vall d'Hebron Hospital, Barcelona, Spain, 5Pharmacology, Medicine, University of California, San Diego, La Jolla, CA

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease affecting the joints and connective tissue and is associated with psoriasis of the skin and nails. There…
  • Abstract Number: 650 • 2017 ACR/ARHP Annual Meeting

    Genome-Wide DNA Methylation, Transcriptomics, and Proteomics of Psoriasis and Psoriatic Arthritis in Monozygotic Twins

    Angela Ceribelli1, Elvezia Maria Paraboschi2, Natasa Isailovic1, Elena Generali1, Michela Robusto2, Maria De Santis1, Giulia Cardamone2, Francesco Sacrini3, Antonio Costanzo3, Stefano Duga2 and Carlo Selmi1, 1Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, 2Laboratory of Medical genetics and RNA biology, Humanitas Research Hospital, Rozzano, Italy, 3Dermatology Unit, Humanitas Research Hospital, Rozzano, Italy

    Background/Purpose: Psoriatic disease is a chronic inflammatory disorder spanning from skin disease (PsO) to psoriatic arthritis (PsA) without known serum biomarkers. The genetic background is…
  • Abstract Number: 651 • 2017 ACR/ARHP Annual Meeting

    Role of Mir-21-5p As a Potential Biomarker of Psoriatic Arthritis and Response to Treatment

    Rohan Machhar1, Justine (Yang) Ye1, Vinod Chandran2 and Dafna D Gladman3, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. miRNA’s are small non coding RNAs whose main function, at a post…
  • « Previous Page
  • 1
  • …
  • 1246
  • 1247
  • 1248
  • 1249
  • 1250
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology